JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Biomarker].

The most serious complication of Kawasaki disease(KD) is coronary artery lesions (CAL), which mainly occur in patients with the incomplete form of KD and intravenous gamma-globulin therapy non-responsiveness (IVIG non-responsiveness). Recently, numerous biomarkers for diagnosis of the incomplete form of KD, endothelial dysfunction, and myocardial disturbance, as well as for the prediction of CAL formation and IVIG non- responsiveness, have been reported. However, a useful single biomarker has yet to be described. Pentraxin 3 (PTX3), endothelin-1(ET-1), brain natriuretic peptide(BNP) and N-terminal pro-brain natriuretic peptide are produced and secreted from vascular and/or myocardial tissue, and are very useful for diagnosis of the incomplete form of KD, and for the prediction of IVIG non-responsiveness and CAL formation in the acute phase. Further- more, some biomarkers are helpful for evaluating chronic coronary arteritis and atheroscle- rosis in the convalescent phase of KD.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app